{
    "status": "ok",
    "totalResults": 543,
    "articles": [
        {
            "source": {
                "id": "wired",
                "name": "Wired"
            },
            "author": "Emily Mullin",
            "title": "The FDA Approves Weight Loss Drug Zepbound, a Wegovy and Ozempic Rival",
            "description": "Eli Lilly is about to release Zepbound, a new entrant in the superheated competition for blockbuster weight loss drugs.",
            "url": "https://www.wired.com/story/fda-approves-weight-loss-drug-zepbound-wegovy-and-ozempic-rival/",
            "urlToImage": "https://media.wired.com/photos/654bdb43b984e409c16f84dd/191:100/w_1280,c_limit/sci-ZepBoundV2_DeviceFront_2pt5.jpg",
            "publishedAt": "2023-11-08T21:33:41Z",
            "content": "The blockbuster weight loss drug Wegovy has a new rival. Today, the US Food and Drug Administration approved a new drug for weight management called Zepbound, made by American pharmaceutical company \u2026 [+3713 chars]"
        },
        {
            "source": {
                "id": "business-insider",
                "name": "Business Insider"
            },
            "author": "Shelby Livingston,Hilary Brueck",
            "title": "Weight-loss drugs just got cheaper \u2014 and better",
            "description": "Eli Lilly priced its new weight-loss drug Zepbound 20% lower than competitor Wegovy, an unusual move in the pharmaceutical world.",
            "url": "https://www.businessinsider.com/zepound-eli-lilly-weight-loss-drug-cost-cheaper-than-wegovy",
            "urlToImage": "https://i.insider.com/654e8c6c36d588dc55cebee9?width=1200&format=jpeg",
            "publishedAt": "2023-11-11T11:43:01Z",
            "content": "More research suggests the medication tirzepatide leads to significant weight loss. Mario Castello/Corbis/VCG\r\n<ul><li>Eli Lilly just debuted its powerful new weight-loss drug, Zepbound.</li><li>Zepb\u2026 [+6074 chars]"
        },
        {
            "source": {
                "id": "abc-news",
                "name": "ABC News"
            },
            "author": "TOM MURPHY AP health writer",
            "title": "Pfizer nixes more study of twice-daily obesity pill treatment",
            "description": "Pfizer shares sank Friday when the drugmaker announced that it was abandoning a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it",
            "url": "https://abcnews.go.com/Business/wireStory/pfizer-nixes-study-daily-obesity-pill-treatment-made-105308243",
            "urlToImage": "https://i.abcnewsfe.com/a/33a04988-cabc-45b4-96dc-0150e2ad6444/wirestory_47fc1b189e3b38e4f1a7233a28f48dd7_16x9.jpg?w=992",
            "publishedAt": "2023-12-01T16:55:38Z",
            "content": "Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it.\r\nThe pharmaceutical company\u2026 [+1871 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Slate Magazine"
            },
            "author": "Heather Tal Murphy",
            "title": "The Reason Every New Pharmaceutical Name Sounds So Bizarre",
            "description": "How did they come up with Ozempic and Zepbound? Rule No. 1: Don't be \"promotional.\"",
            "url": "https://slate.com/technology/2023/11/zepbound-weight-loss-drug-ozempic-pharmaceutical-names.html",
            "urlToImage": "https://compote.slate.com/images/046bf507-a55c-4613-a669-95ce6cfa6355.jpeg?crop=1987%2C1325%2Cx0%2Cy0&width=1560",
            "publishedAt": "2023-11-11T14:30:00Z",
            "content": "This week, the world simultaneously got yet another weight-loss drug and a reason to wonder why pharmaceuticals have the names that they have. Zepbound is the name that multibillion dollar pharmaceut\u2026 [+8864 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "New Atlas"
            },
            "author": "Bronwyn Thompson",
            "title": "US and UK give the green light to powerful weight loss drug",
            "description": "The US has officially got a homegrown hero in the burgeoning global industry of effective weight-loss treatments, with the FDA approval of Eli Lilly\u2019s Zepbound. The company has announced the once-a-week injectable drug's cost, dosages, insurance subsidies and\u2026",
            "url": "https://newatlas.com/medical/weight-loss-drug-fda/",
            "urlToImage": "https://assets.newatlas.com/dims4/default/dfda0e7/2147483647/strip/true/crop/6000x3150+0+113/resize/1200x630!/quality/90/?url=http%3A%2F%2Fnewatlas-brightspot.s3.amazonaws.com%2F16%2F33%2F74384ae5424c8c3f0f47d4c3a398%2Fdepositphotos-457361084-xl.jpg&na.image_optimisation=0",
            "publishedAt": "2023-11-09T03:01:30Z",
            "content": "The US has officially got a homegrown hero in the burgeoning global industry of effective weight-loss treatments, with the FDA approval of Eli Lillys Zepbound. The company has announced the once-a-we\u2026 [+4060 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "barrons.com",
            "title": "AstraZeneca Is Getting Into the Weight-Loss Drug Game. The Stock Needs a Boost",
            "description": "AstraZeneca is the latest pharmaceutical company looking to get in on the hype around weight-loss drugs. Stockholders welcomed the move as its shares have lagged behind peers Eli Lilly and Novo Nordisk.#astrazeneca #elililly #novonordisk",
            "url": "https://biztoc.com/x/148765889b72cb95",
            "urlToImage": "https://c.biztoc.com/p/148765889b72cb95/s.webp",
            "publishedAt": "2023-11-09T16:08:17Z",
            "content": "AstraZeneca is the latest pharmaceutical company looking to get in on the hype around weight-loss drugs. Stockholders welcomed the move as its shares have lagged behind peers Eli Lilly and Novo Nordi\u2026 [+76 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Derek Saul, Forbes Staff, \n Derek Saul, Forbes Staff\n https://www.forbes.com/sites/dereksaul/",
            "title": "Pfizer Pulls Experimental Twice-Daily Weight Loss Drug\u2014Shares Slide 6% To Multiyear Low",
            "description": "Investors\u2019 have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight loss drug makers Eli Lilly (shares up 60%) and Novo Nordisk (shares up 50%).",
            "url": "https://www.forbes.com/sites/dereksaul/2023/12/01/pfizer-pulls-experimental-twice-daily-weight-loss-drug-shares-slide-6-to-multiyear-low/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6569efef15a335af1bc4a0d6/0x0.jpg?format=jpg&crop=2341,1318,x0,y3,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-12-01T14:43:38Z",
            "content": "Pfizer announced Friday it wont move forward with trials for a twice-daily regimen of its weight-loss pill intended to compete with Ozempic and other booming drugs in the class, sending Pfizers stock\u2026 [+2261 chars]"
        },
        {
            "source": {
                "id": "time",
                "name": "Time"
            },
            "author": "Jamie Ducharme",
            "title": "Should We End Obesity?",
            "description": "Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are massively popular. Doctors can't agree on whether that's a good thing.",
            "url": "https://time.com/6330809/ozempic-wegovy-mounjaro-healthy/",
            "urlToImage": "https://api.time.com/wp-content/uploads/2023/11/MariaelenaCaputi_Ozempic_horizontal.jpg?quality=85",
            "publishedAt": "2023-11-07T12:00:00Z",
            "content": "Its unusual for a medication to become a household name; even more uncommon for its branding to become, like Advil, shorthand for an entire class of products; and rarest of all, for it to change not \u2026 [+18714 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "cnbc.com",
            "title": "Pfizer wants in on the weight loss drug market",
            "description": "As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer's experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space's dom\u2026",
            "url": "https://biztoc.com/x/9d738a2c85e89bd7",
            "urlToImage": "https://c.biztoc.com/p/9d738a2c85e89bd7/og.webp",
            "publishedAt": "2023-11-13T15:22:16Z",
            "content": "As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market.Analysts say upcoming data on Pfizer's experimental obesity pill, danuglipron, will be crucial in determining\u2026 [+293 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Britney Nguyen, Forbes Staff, \n Britney Nguyen, Forbes Staff\n https://www.forbes.com/sites/britneynguyen/",
            "title": "Roche Will Buy Obesity And Diabetes Drugmaker Carmot Therapeutics In $2.7 Billion Deal",
            "description": "Roche said Carmot Therapeutics\u2019 research and development portfolio \u201chas great potential to treat obesity, diabetes and potentially other diseases\u201d both on its own and in combination with Roche\u2019s assets.",
            "url": "https://www.forbes.com/sites/britneynguyen/2023/12/04/roche-will-buy-obesity-and-diabetes-drugmaker-carmot-therapeutics-in-27-billion-deal/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/656e25a4ad16afaa37edede2/0x0.jpg?format=jpg&crop=1272,716,x0,y127,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-12-04T19:24:10Z",
            "content": "Swiss pharmaceuticals company Roche agreed to acquire U.S.-based weight-loss drugmaker Carmot Therapeutics, which develops anti-obesity and diabetes drugs, for $2.7 million, according to a press rele\u2026 [+4156 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Zinnia Lee, Forbes Staff, \n Zinnia Lee, Forbes Staff\n https://www.forbes.com/sites/zinnialee/",
            "title": "Tencent-Backed AI Drug Discovery Startup Xtalpi Files For Hong Kong IPO",
            "description": "Xtalpi\u2019s last private fundraising was a $380 million Series D round in October 2021 that valued the company at about $2 billion.",
            "url": "https://www.forbes.com/sites/zinnialee/2023/12/01/tencent-backed-ai-drug-discovery-startup-xtalpi-files-for-hong-kong-ipo/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6569ad0c82cf45e28c084682/0x0.jpg?format=jpg&crop=3000,1688,x0,y224,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-12-01T10:05:07Z",
            "content": "Xtalpi operates autonomous labs in Shenzhen, Shanghai and Boston.\r\nXtalpi \r\nXtalpi, a Shenzhen-based company which uses artificial intelligence to find chemical compounds that could be developed into\u2026 [+3158 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Derek Saul, Forbes Staff, \n Derek Saul, Forbes Staff\n https://www.forbes.com/sites/dereksaul/",
            "title": "Pfizer Stock Hits 3-Year Low\u2014Down 50% From 2021 Peak",
            "description": "Excluding a brief early 2020 plunge, Pfizer shares are now trading at their lowest level since 2016.",
            "url": "https://www.forbes.com/sites/dereksaul/2023/11/13/pfizer-stock-hits-3-year-low-down-50-from-2021-peak/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/65528ed147e90d7670350551/0x0.jpg?format=jpg&crop=4000,2250,x0,y186,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-13T21:08:53Z",
            "content": "Pfizer shares tumbled again Monday, continuing the pharmaceutical giants struggles tied to declining demand for its Covid-19 productsand essentially wiping out the entirety of the firms peak pandemic\u2026 [+2446 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "New York Post"
            },
            "author": "Brooke Kato",
            "title": "Eli Lilly weight loss drug Zepbound approved by the FDA",
            "description": "Move over, Ozempic \u2014\u00a0there's a new drug in town.",
            "url": "https://nypost.com/2023/11/08/lifestyle/eli-lilly-weight-loss-drug-zepbound-approved-by-the-fda/",
            "urlToImage": "https://nypost.com/wp-content/uploads/sites/2/2023/11/NYPICHPDPICT000010800313.jpg?quality=75&strip=all&w=1024",
            "publishedAt": "2023-11-08T20:45:51Z",
            "content": "Move over, Ozempic \u00a0there\u2019s a new drug in town.\r\nEli Lilly\u2019s Zepbound, with the active ingredient tirzepatide, has been approved by the Food and Drug Administration for use by obese or overweight adu\u2026 [+3700 chars]"
        },
        {
            "source": {
                "id": "nbc-news",
                "name": "NBC News"
            },
            "author": "Berkeley Lovelace Jr.",
            "title": "What to know about Zepbound, Eli Lilly\u2019s new weight loss drug",
            "description": "A new weight loss drug has been approved that promises to be the most effective medication yet.",
            "url": "https://www.nbcnews.com/health/health-news/zepbound-eli-lilly-weight-loss-drug-what-to-know-rcna124237",
            "urlToImage": "https://media-cldnry.s-nbcnews.com/image/upload/t_nbcnews-fp-1200-630,f_auto,q_auto:best/rockcms/2023-11/231108-zepbound-mn-1600-c9b4aa.jpg",
            "publishedAt": "2023-11-09T10:00:00Z",
            "content": "A new weight loss drug has been approved that promises to be the most effective medication yet. How is Zepbound, the weekly injectable drug thats expected to be available shortly after Thanksgiving, \u2026 [+6009 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The Boston Globe"
            },
            "author": "Robert Weisman",
            "title": "EMD Serono headquarters plans to join biopharma cluster in Boston\u2019s Seaport",
            "description": "The company will join more than two dozen life sciences companies, including Vertex and Eli Lilly, in the neighborhood.",
            "url": "https://www.bostonglobe.com/2023/11/14/business/emd-serono-merck-seaport-ms-cancer-drugs/",
            "urlToImage": "https://bostonglobe-prod.cdn.arcpublishing.com/resizer/N-GOAA5hxxwaK-vGjizNBhtOPyo=/506x0/cloudfront-us-east-1.images.arcpublishing.com/bostonglobe/7L43K2MFPZFIPAG7F3DEM6RH7A.jpg",
            "publishedAt": "2023-11-14T17:33:44Z",
            "content": "EMD Serono, the American drug development arm of Germanys Merck KGaA, plans to move its headquarters from the South Shore town of Rockland to Bostons Seaport district next summer.\r\nThe company will j\u2026 [+2974 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "MedCity News"
            },
            "author": "FRANK VINLUAN - MEDCITY NEWS",
            "title": "Novo Nordisk Plans \u20ac2B Site Expansion As GLP-1 Drug Demand Grows",
            "description": "Novo Nordisk's planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already one of the company\u2019s largest for making diabetes products.\u2026",
            "url": "https://medcitynews.com/2023/11/novo-nordisk-plans-e2b-site-expansion-as-glp-1-drug-demand-grows/",
            "urlToImage": "https://medcitynews.com/uploads/2023/08/GettyImages-633295152-1.jpg",
            "publishedAt": "2023-11-28T15:02:01Z",
            "content": "Demand for Novo Nordisks metabolic disorder drugs has far outstripped its ability to supply them, contributing to shortages of these products. The pharmaceutical company is positioning itself to meet\u2026 [+2665 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The Atlantic"
            },
            "author": "Helen Lewis",
            "title": "The Other Ozempic Revolution",
            "description": "Weight-loss drugs affect identities and relationships as much as waistlines.",
            "url": "https://www.theatlantic.com/ideas/archive/2023/11/ozempic-wegovy-social-revolution-weight-loss/676002/?utm_source=feed",
            "urlToImage": null,
            "publishedAt": "2023-11-19T12:30:00Z",
            "content": "On Labor Day weekend, 35 excited guests arrived at a campground in Newark, Ohio, for a retreat dedicated to \u201cfat joy\u201d\u2014a place where people could swim, dance, do yoga, roast marshmallows, and sleep in\u2026 [+17476 chars]"
        },
        {
            "source": {
                "id": "time",
                "name": "Time"
            },
            "author": "Alice Park",
            "title": "What You Need to Know About Compounded Versions of Popular Weight Loss Drugs",
            "description": "You can get versions of Wegovy and Ozempic from a compounding pharmacy. But that doesn't necessarily mean you should.",
            "url": "https://time.com/6301552/weight-loss-drugs-compounding-pharmacies/",
            "urlToImage": "https://api.time.com/wp-content/uploads/2023/11/Health-WeightLossdrugsUbiquity-1.jpg?quality=85",
            "publishedAt": "2023-11-20T17:36:14Z",
            "content": "With social media fueling the huge demand for drugs like Ozempic, Rybelsus, Wegovy, and Mounjaro, which are helping people to lose more weight than any previous weight loss medications, its no surpri\u2026 [+11855 chars]"
        },
        {
            "source": {
                "id": "cbs-news",
                "name": "CBS News"
            },
            "author": "Alexander Tin",
            "title": "FDA approves a new weight loss drug, Zepbound from Eli Lilly",
            "description": "The medication, tirzepatide, was previously approved as Mounjaro for diabetes and will now be marketed as Zepbound for weight loss.",
            "url": "https://www.cbsnews.com/news/fda-approves-new-weight-loss-drug-zepbound-eli-lilly/",
            "urlToImage": "https://assets2.cbsnewsstatic.com/hub/i/r/2023/04/28/ce76db44-5ec0-4032-91e5-1547e4c1e7f0/thumbnail/1200x630g8/6339c54377236e92a20fe66b5ff61190/ap23117552285654.jpg?v=e2a739f263a10b93b27cae9568461c29",
            "publishedAt": "2023-11-08T18:25:59Z",
            "content": "The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight lo\u2026 [+3578 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Ty Roush, Forbes Staff, \n Ty Roush, Forbes Staff\n https://www.forbes.com/sites/tylerroush/",
            "title": "Novo Nordisk Sues Two Florida Pharmacies For Allegedly Selling Impure Weight-Loss Drugs",
            "description": "The Danish drugmaker claims one pharmacy is adding a banned substance to its drugs.",
            "url": "https://www.forbes.com/sites/tylerroush/2023/11/30/novo-nordisk-sues-two-florida-pharmacies-for-allegedly-selling-impure-weight-loss-drugs/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6568a324900b7fd589cdc16b/0x0.jpg?format=jpg&crop=5197,3467,x0,y0,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-30T14:59:06Z",
            "content": "Novo Nordiskmanufacturer of diabetes and weight-loss drugs Ozempic and Wegovyfiled lawsuits against two pharmacies after tests concluded their products were impure, according to an announcement Thurs\u2026 [+3504 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "New Atlas"
            },
            "author": "Paul McClure",
            "title": "One-dose drug reduced genetic bad cholesterol by 94% for almost a year",
            "description": "Researchers have conducted the first human trials of a new drug, lepodisiran, and found that a single injection reduced lipoprotein(a) \u2013 a \u2018bad\u2019 cholesterol with a genetic basis \u2013 to undetectable levels for almost a year. It has the potential to eliminate a r\u2026",
            "url": "https://newatlas.com/medical/lepodisiran-reduced-lipoprotein-a-by-94-percent-for-almost-a-year/",
            "urlToImage": "https://assets.newatlas.com/dims4/default/41b3ffc/2147483647/strip/true/crop/2000x1050+0+142/resize/1200x630!/quality/90/?url=http%3A%2F%2Fnewatlas-brightspot.s3.amazonaws.com%2F12%2Ff9%2F8735cfe64ca4b44ba9ce2387c572%2Fdepositphotos-43422131-l.jpg&na.image_optimisation=0",
            "publishedAt": "2023-11-14T01:24:17Z",
            "content": "Researchers have conducted the first human trials of a new drug, lepodisiran, and found that a single injection reduced lipoprotein(a) a bad cholesterol with a genetic basis to undetectable levels fo\u2026 [+3575 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "R-bloggers.com"
            },
            "author": "rOpenSci - open tools for open science",
            "title": "Introducing rOpenSci Mentors \u2013 Cohort 2023-2024",
            "description": "One important aspect of rOpenSci\u2019s mission is to build capacity and promote passionate community members who help the open science and open source software community grow and improve.\nThe rOpenSci Champions Program is a unique opportunity for us...\nContinue r\u2026",
            "url": "https://www.r-bloggers.com/2023/11/introducing-ropensci-mentors-cohort-2023-2024/",
            "urlToImage": "https://www.r-bloggers.com/wp-content/uploads/2016/04/R_02_2016-05-01.png",
            "publishedAt": "2023-11-29T00:00:00Z",
            "content": "One important aspect of rOpenScis mission is to build capacity and promote passionate community members who help the open science and open source software community grow and improve.\r\nThe rOpenSci Ch\u2026 [+7089 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "AstraZeneca Is Making A $2 Billion Bet To Rival Lilly, Novo In Obesity Drugs",
            "description": "The company is licensing a new GLP-1 drug in the hopes of taking on Novo and Lilly.",
            "url": "https://www.investors.com/news/technology/azn-stock-astrazeneca-earnings-q3-2023/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2020/12/Stock-AstraZeneca-03-adobe.jpg",
            "publishedAt": "2023-11-09T15:28:46Z",
            "content": "Shares of AZN stock popped Thursday after AstraZeneca (AZN) said it would spend up to $2.01 billion to license an experimental weight-loss drug from Eccogene.\r\nXThe news comes a day after Eli Lilly (\u2026 [+2574 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "Pfizer Halts Development Of Twice-Daily Weight-Loss Drug; PFE Stock Slides",
            "description": "Pfizer said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell.",
            "url": "https://www.investors.com/news/technology/pfe-stock-slides-after-pfizers-latest-setback-for-weight-loss-drug/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2022/01/Stock-pfizersign-05-adobe.jpg",
            "publishedAt": "2023-12-01T15:42:22Z",
            "content": "Pfizer (PFE) said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell in early trading, as the company said it would focus on a \u2026 [+2091 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Emmy Lucas, Forbes Staff, \n Emmy Lucas, Forbes Staff\n https://www.forbes.com/sites/emmylucas/",
            "title": "U.S. Sees Weakest Jobs Growth Since 2021, Best Employers For Veterans And LinkedIn\u2019s New Feats",
            "description": "The published version of this week\u2019s Forbes Careers newsletter brings the latest news, insights and ideas about the workplace straight to your inbox every Tuesday.",
            "url": "https://www.forbes.com/sites/emmylucas/2023/11/07/us-sees-weakest-jobs-growth-since-2021-best-employers-for-veterans-and-linkedins-new-feats/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/6228bbfb01bf1836c5965ee9/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-07T18:02:14Z",
            "content": "Click here to get on the newsletter list!\r\nThe U.S. added 150,000 jobs in October, falling short of economist estimates, according to the latest jobs report from BLS. \r\ngetty\r\nJob growth seems to be \u2026 [+3861 chars]"
        },
        {
            "source": {
                "id": "fortune",
                "name": "Fortune"
            },
            "author": "Reuters",
            "title": "Novo Nordisk announces new $2.3 billion investment in France to keep up with soaring demand for weight-loss drugs",
            "description": "U.S. rival Eli Lilly last week laid out plans to build a $2.5 billion manufacturing site in Germany.",
            "url": "https://fortune.com/europe/2023/11/23/novo-nordisk-france-drug-production/",
            "urlToImage": "https://content.fortune.com/wp-content/uploads/2023/11/GettyImages-1247410165-e1700737856413.jpg?resize=1200,600",
            "publishedAt": "2023-11-23T11:42:35Z",
            "content": "Novo Nordisk plans to invest more than 16 billion Danish crowns ($2.34 billion) to boost production of its weight-loss drugs at a site in Chartres, France, scrambling to keep up with soaring demand.T\u2026 [+1208 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Euronews"
            },
            "author": null,
            "title": "Danish pharmaceutical invests \u20ac2.1 billion in France",
            "description": "On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site to expand the capacity and manufacturing of a blockbuster anti-obesity drug.",
            "url": "https://www.euronews.com/2023/11/24/danish-pharmaceutical-invests-21-billion-in-france",
            "urlToImage": "https://static.euronews.com/articles/stories/08/06/27/60/1000x563_cmsv2_2417f8a1-4251-5f27-9ce3-5e7e3c1e7090-8062760.jpg",
            "publishedAt": "2023-11-24T14:11:30Z",
            "content": "On Thursday, Danish pharmaceutical giant Novo Nordisk announced a major investment in a French production site to expand the capacity and manufacturing of a blockbuster anti-obesity drug.\r\n On Thursd\u2026 [+2899 chars]"
        },
        {
            "source": {
                "id": "abc-news-au",
                "name": "ABC News (AU)"
            },
            "author": "Elise Worthington",
            "title": "A new diabetes drug quietly launched in Australia in September. It's already out of stock",
            "description": "A new diabetes medication being prescribed off-label for weight loss is already experiencing shortages, just weeks after becoming available in Australia.",
            "url": "https://www.abc.net.au/news/2023-11-30/mounjaro-weight-loss-diabetes-drug-shortage/103170324",
            "urlToImage": "https://live-production.wcms.abc-cdn.net.au/fd0e5b28054db22d295b3472acb142e9?impolicy=wcms_crop_resize&cropH=2813&cropW=5000&xPos=0&yPos=260&width=862&height=485",
            "publishedAt": "2023-11-30T02:48:56Z",
            "content": "A new diabetes medication being prescribed off-label for weight loss is already experiencing shortages, just weeks after becoming available in Australia.\r\nKey points:\r\n<ul><li>Despite only being rele\u2026 [+7612 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The Cut"
            },
            "author": "Bindu Bansinath",
            "title": "What to Know About Zepbound",
            "description": "The diabetes drug Mounjaro has now been approved for weight loss under the brand name Zepbound. The two drugs are tirzepatides, which help patients lose weight more effectively than semaglutides like Ozempic or Wegovy.",
            "url": "http://www.thecut.com/article/what-to-know-about-mounjaro-zepbound.html",
            "urlToImage": "https://pyxis.nymag.com/v1/imgs/9fb/bd5/d5f52b3657a7e611388d308b2f1c14417e-zepbound.1x.rsocial.w1200.jpg",
            "publishedAt": "2023-11-28T20:18:00Z",
            "content": "While Ozempic continues to surge in popularity, theres another diabetes drug and weight loss agent on the rise. The Eli Lillymanufactured drug tirzepatide hit the market in May 2022 under the brand n\u2026 [+6025 chars]"
        },
        {
            "source": {
                "id": "fortune",
                "name": "Fortune"
            },
            "author": "Paula Doenecke, Bloomberg",
            "title": "Roche pushes to catch up to Novo Nordisk\u2019s Wegovy with $3.1bn deal for obesity drugmaker Carmot",
            "description": "Though Carmot\u2019s drugs are still in early stages of development, the deal could lead to a competitor to the likes of Wegovy and Eli Lilly & Co.\u2019s Zepbound.",
            "url": "https://fortune.com/europe/2023/12/04/roche-novo-nordisk-wegovy-31-billion-deal-obesity-drugmaker-carmot/",
            "urlToImage": "https://content.fortune.com/wp-content/uploads/2023/12/GettyImages-1236433985-e1701683461556.jpg?resize=1200,600",
            "publishedAt": "2023-12-04T09:53:43Z",
            "content": "Roche Holding AG agreed to pay as much as $3.1 billion for Carmot Therapeutics Inc., a developer of a new type of weight-loss treatment thats sparked a pharma industry gold rush.The deal for three ex\u2026 [+2570 chars]"
        },
        {
            "source": {
                "id": "fortune",
                "name": "Fortune"
            },
            "author": "Madison Muller, Bloomberg",
            "title": "FDA approves yet another weight loss drug to compete against blockbuster sellers Ozempic and Wegovy",
            "description": "Eli Lilly\u2019s diabetes drug tirzepatide gained US approval for treating patients with obesity under a new name, Zepbound.",
            "url": "https://fortune.com/2023/11/08/eli-lilly-weight-loss-drug-fda-approval-ozempic-wegovy-zepbound/",
            "urlToImage": "https://content.fortune.com/wp-content/uploads/2023/11/GettyImages-1253661817-e1699467360844.jpg?resize=1200,600",
            "publishedAt": "2023-11-08T18:19:13Z",
            "content": "Eli Lillys diabetes drug tirzepatide gained US approval for treating patients with obesity under a new name, Zepbound, unlocking blockbuster sales potential in a market thats expected to hit $100 bil\u2026 [+1025 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Forbes"
            },
            "author": "Alex Zhavoronkov, PhD, Contributor, \n Alex Zhavoronkov, PhD, Contributor\n https://www.forbes.com/sites/alexzhavoronkov/",
            "title": "Can This Pharma CEO Change The Way Drugs Are Discovered, Developed, And Delivered With AI?",
            "description": "October 27, 2023 turned into Sanofi's \"black Friday\" as the company announced its intent to invest in internal R&D. The market  did not get the message. Here is why.",
            "url": "https://www.forbes.com/sites/alexzhavoronkov/2023/11/08/can-this-pharma-ceo-change-the-way-drugs-are-discovered-developed-and-delivered-with-ai/",
            "urlToImage": "https://imageio.forbes.com/specials-images/imageserve/654b61c31250f14f3e91d1ab/0x0.jpg?format=jpg&crop=2499,1407,x0,y586,safe&height=900&width=1600&fit=bounds",
            "publishedAt": "2023-11-08T14:12:23Z",
            "content": "Pharma Fireside Chat between Paul Hudson, CEO of Sanofi and David Flores, CEO at BioCentury China ... [+] Healthcare, November 3, 2023, Shanghai, China\r\nAlex Zhavoronkov, PhD\r\nNovember 2022-2023 stoc\u2026 [+9865 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "CNBC"
            },
            "author": "Angelica Peebles",
            "title": "Novo Nordisk's weight loss drug Wegovy slashes risk of serious heart events",
            "description": "The findings could expand use of Wegovy and help Novo maintain its lead over Eli Lilly, whose competing weight-loss drug Zepbound was just approved in the U.S.",
            "url": "https://www.cnbc.com/2023/11/11/weight-loss-drug-wegovy-slashes-risk-of-serious-heart-complications.html",
            "urlToImage": "https://image.cnbcfm.com/api/v1/image/107310828-1696353063804-gettyimages-1692436787-64393_48_ms_1931.jpeg?v=1696353110&w=1920&h=1080",
            "publishedAt": "2023-11-11T13:30:00Z",
            "content": "Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity.\u00a0\r\nNovo Nordisk's Wegovy cut \u2026 [+4266 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investopedia"
            },
            "author": "Staff Author",
            "title": "Eli Lilly Shares Hit All-Time High After FDA Approves Drug for Weight-Loss Treatment",
            "description": "Eli Lilly shares hit an all-time high after receiving FDA approval for Zepbound, an injectable treatment to help people lose weight.",
            "url": "https://www.investopedia.com/eli-lilly-shares-hit-all-time-high-after-fda-approves-drug-for-weight-loss-treatment-8399595",
            "urlToImage": "https://www.investopedia.com/thmb/YWiMy17lA2tsanEbg0IOgU9Cn4g=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-521503314-a3ef2646f74e4a1aa2226086dce41a42.jpg",
            "publishedAt": "2023-11-08T22:41:08Z",
            "content": "<ul><li>Eli Lilly shares hit an all-time high after receiving FDA approval for Zepbound, an injectable medicine to help people lose weight.</li><li>The drug's active ingredient, tirzepatide, had prev\u2026 [+2031 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Wccftech"
            },
            "author": "Rohail Saleem",
            "title": "Eli Lilly and Company\u2019s Weight Loss Drug Zepbound Approved by FDA; Will Be Available at $1,060 Per 6 Doses",
            "description": "The GLP-1 phenomenon is truly on the role, particularly in the US. Now, Eli Lilly and Company has moved one step closer to realizing the $100 billion annual sales potential for GLP-1 drugs by winning a key FDA approval. Eli Lilly and Company's Mounjaro inject\u2026",
            "url": "https://wccftech.com/eli-lilly-and-companys-weight-loss-drug-zepbound-approved-by-fda-will-be-available-at-1060-per-6-doses/",
            "urlToImage": "https://cdn.wccftech.com/wp-content/uploads/2023/11/images-2.jpeg",
            "publishedAt": "2023-11-08T18:10:17Z",
            "content": "This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.\r\nThe GLP-1 phenomenon is truly on the role, particularly in \u2026 [+2887 chars]"
        },
        {
            "source": {
                "id": "fortune",
                "name": "Fortune"
            },
            "author": "Ryan Hogg",
            "title": "Novo Nordisk faces first real test as Eli Lilly wins approval for a weight loss-aiding drug",
            "description": "U.S. regulators signed off on Eli Lilly\u2019s diabetes drug Zepbound, which can also be used to aid weight loss like Wegovy and Ozempic.",
            "url": "https://fortune.com/europe/2023/11/09/novo-nordisk-rival-eli-lilly-zepbound-approval/",
            "urlToImage": "https://content.fortune.com/wp-content/uploads/2023/11/GettyImages-1244662753-e1699530818595.jpg?resize=1200,600",
            "publishedAt": "2023-11-09T12:24:00Z",
            "content": "It took some time, but Novo Nordisk may be facing the first real test of its dominance in the weight loss market after pharmaceutical giant Eli Lilly won approval for its own Wegovy rival.U.S. regula\u2026 [+2616 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "[Removed]"
            },
            "author": null,
            "title": "[Removed]",
            "description": "[Removed]",
            "url": "https://removed.com",
            "urlToImage": null,
            "publishedAt": "1970-01-01T00:00:00Z",
            "content": "[Removed]"
        },
        {
            "source": {
                "id": null,
                "name": "[Removed]"
            },
            "author": null,
            "title": "[Removed]",
            "description": "[Removed]",
            "url": "https://removed.com",
            "urlToImage": null,
            "publishedAt": "1970-01-01T00:00:00Z",
            "content": "[Removed]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "December Looks Great For Investors Who Own 9 Stocks",
            "description": "Investors can only hope stocks do as well in December as they did in November.",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-december-looks-great-for-investors-who-own-stocks/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2020/11/Stock-december-02-adobe.jpg",
            "publishedAt": "2023-12-01T13:00:11Z",
            "content": "Investors can only hope stocks do as well in December as they did in November. There are definitely some S&amp;P 500 stocks that glisten in the last month of the year.\r\nXNine S&amp;P 500 stocks inclu\u2026 [+3097 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, Palantir, These Huge Winners",
            "description": "Roku vaulted 50% to become Ark Innovation's top holding.",
            "url": "https://www.investors.com/news/cathie-wood-ark-innovation-just-had-its-best-week-ever-thanks-to-11-huge-winners/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg",
            "publishedAt": "2023-11-06T12:45:51Z",
            "content": "Cathie Wood's Ark Innovation ETF (ARKK) typically outpaces the overall market to the upside and downside.\u00a0Last week, the S&amp;P 500, Dow Jones and Nasdaq had their best gains of 2023. But the Ark In\u2026 [+8241 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "Novo Nordisk Stock Skids \u2014 But These Weight-Loss Results Are 'Hard To Ignore'",
            "description": "Patients who took Wegovy for five years had a 70% reduced risk of developing diabetes.",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-can-weight-loss-drugs-prevent-diabetes/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "publishedAt": "2023-11-13T16:25:07Z",
            "content": "Novo Nordisk (NVO) stock slumped Monday even though the company unveiled promising test results that suggest a new class of weight-loss drugs could prevent some patients from developing diabetes.\r\nXT\u2026 [+3682 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Wccftech"
            },
            "author": "Rohail Saleem",
            "title": "Broadside Against Eli Lilly and Company: Novo Nordisk Hypes the 20% Reduction in Death Risk Offered by Its GLP-1 Weight Loss Drug",
            "description": "A price war waged by big pharma usually works in the favor of consumers, in the short term at least, or until the victor captures the market and establishes a monopoly. Eli Lilly and Company unveiled its opening gambit earlier this week by pricing its GLP-1 w\u2026",
            "url": "https://wccftech.com/broadside-against-eli-lilly-and-company-novo-nordisk-hypes-the-20-reduction-in-death-risk-offered-by-its-glp-1-weight-loss-drug/",
            "urlToImage": "https://cdn.wccftech.com/wp-content/uploads/2023/11/overweight-young-woman-eating-junk-food-stockpack-gettyimages-scaled-jpg.webp",
            "publishedAt": "2023-11-11T14:49:32Z",
            "content": "This is not investment advice. The author has no position in any of the stocks mentioned. Wccftech.com has a disclosure and ethics policy.\r\nA price war waged by big pharma usually works in the favor \u2026 [+3332 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Japan Today"
            },
            "author": null,
            "title": "Novo to launch anti-obesity drug Wegovy in Asia with February Japan roll-out",
            "description": "Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep up with demand in existing markets. The Danish company has picked Japan as\u2026",
            "url": "https://japantoday.com/category/national/novo-to-launch-wegovy-in-asia-with-february-japan-roll-out",
            "urlToImage": null,
            "publishedAt": "2023-11-23T21:28:41Z",
            "content": "Novo Nordisk will launch its hugely popular anti-obesity drug Wegovy in Japan on Feb. 22 next year, its first launch in Asia, the company said on Thursday, even as it struggles to keep up with demand\u2026 [+1536 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "New York Post"
            },
            "author": "Adriana Diaz",
            "title": "Woman dies after taking Ozempic to slim down for daughter\u2019s wedding: \u2018She shouldn\u2019t be gone\u2019",
            "description": "\"It's just not worth it, it's not worth it at all,\" Roy Webster said.",
            "url": "https://nypost.com/2023/11/06/lifestyle/woman-dies-after-taking-ozempic-to-slim-down-for-wedding/",
            "urlToImage": "https://nypost.com/wp-content/uploads/sites/2/2023/11/NYPICHPDPICT000071896455.jpg?quality=75&strip=all&w=1024",
            "publishedAt": "2023-11-07T01:20:02Z",
            "content": "An Australian woman who took Ozempic to shed a few pounds before her daughter\u2019s wedding has died from gastrointestinal illness now her husband is warning that the medication is \u201cnot worth it at all.\u201d\u2026 [+4688 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "International Business Times"
            },
            "author": "AFP News",
            "title": "Novo Nordisk Spends Big In France To Expand Obesity Drug Capacity",
            "description": "Danish pharmaceutical giant Novo Nordisk will announce Thursday a major investment in a French production site to expand capacity for a blockbuster anti-obesity drug, the French presidency said.",
            "url": "https://www.ibtimes.com/novo-nordisk-spends-big-france-expand-obesity-drug-capacity-3719274",
            "urlToImage": "https://d.ibtimes.com/en/full/4500636/some-say-weight-loss-drugs-market-could-grow-100-billion-2030.jpg",
            "publishedAt": "2023-11-23T14:36:29Z",
            "content": "Danish pharmaceutical giant Novo Nordisk will announce Thursday a major investment in a French production site to expand capacity for a blockbuster anti-obesity drug, the French presidency said.\r\nIn \u2026 [+2290 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Mirova Sells 3,182 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Mirova lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 11.0% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 25,716 shares of the c\u2026",
            "url": "https://www.etfdailynews.com/2023/11/28/mirova-sells-3182-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-28T19:44:49Z",
            "content": "Mirova lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 11.0% during the 2nd quarter, according to its most recent disclosure with the Securities &amp; Exchange Com\u2026 [+6618 chars]"
        },
        {
            "source": {
                "id": "time",
                "name": "Time"
            },
            "author": "Alice Park",
            "title": "FDA Approves Zepbound, the Most Potent Weight Loss Drug Yet",
            "description": "Zepbound, made by Eli Lilly, is the newest FDA-approved drug for weight loss. (It was previously a diabetes treatment known as Mounjaro.)",
            "url": "https://time.com/6333255/fda-approval-zepbound-tirzepatide-mounjaro-weight-loss/",
            "urlToImage": "https://api.time.com/wp-content/uploads/2023/11/ZepBoundV2_DeviceFront_2pt5.jpg?quality=85",
            "publishedAt": "2023-11-09T13:32:10Z",
            "content": "Weight loss drugs have dominated the headlines over the past year, and now theres a new medication that may be the most effective one yet.\r\nOn Nov. 11, the U.S. Food and Drug Administration (FDA) app\u2026 [+7368 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "The Week Magazine"
            },
            "author": "theweekonlineeditors@futurenet.com (Harold Maass, The Week US)",
            "title": "The daily business briefing: November 9, 2023",
            "description": "Actors and studios reach a deal to end strike, Disney reports better-than-expected quarterly profit, and more",
            "url": "https://theweek.com/business/the-daily-business-briefing-november-9-2023",
            "urlToImage": "https://cdn.mos.cms.futurecdn.net/roPBuwEe9N78cjFnTMNPZh-1200-80.jpg",
            "publishedAt": "2023-11-09T13:14:05Z",
            "content": "1. Actors, Hollywood studios reach deal to end strike\r\nSAG-AFTRA, the union representing striking actors, reached a tentative agreement with Hollywood studios on Wednesday to end the 118-day actors s\u2026 [+4057 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Sold by Payden & Rygel",
            "description": "Payden & Rygel lowered its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 70.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 30,720 shares of the company\u2019s \u2026",
            "url": "https://www.etfdailynews.com/2023/11/19/eli-lilly-and-company-nyselly-shares-sold-by-payden-rygel/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-19T16:24:44Z",
            "content": "Payden &amp; Rygel lowered its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 70.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange \u2026 [+5886 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Sold by Hoylecohen LLC",
            "description": "Hoylecohen LLC reduced its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,495 shares of the c\u2026",
            "url": "https://www.etfdailynews.com/2023/11/05/eli-lilly-and-company-nyselly-shares-sold-by-hoylecohen-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-05T19:06:42Z",
            "content": "Hoylecohen LLC reduced its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (\u2026 [+7322 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly plans single-digit billion dollar new German plant -sources",
            "description": "(marketscreener.com) BERLIN -U.S. pharma company Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the company called a news conference for Friday.https\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-plans-single-digit-billion-dollar-new-German-plant-sources-45363529/",
            "urlToImage": "https://www.marketscreener.com/images/reuters/2021-03/2021-03-09T172726Z_1_LYNXMPEH2814Y-OCABS_RTROPTP_3_CBUSINESS-US-LILLY-MOVES.JPG",
            "publishedAt": "2023-11-15T19:36:02Z",
            "content": "BERLIN (Reuters) -U.S. pharma company Eli Lilly plans an investment in the single-digit billion dollar range in a new plant in western Germany, people familiar with the matter told Reuters after the \u2026 [+2704 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Purchased by Commerce Bank",
            "description": "Commerce Bank boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 13.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 135,886 shares of\u2026",
            "url": "https://www.etfdailynews.com/2023/11/08/eli-lilly-and-company-nyselly-shares-purchased-by-commerce-bank/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-08T21:00:41Z",
            "content": "Commerce Bank boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 13.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securi\u2026 [+6812 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Rating Reiterated by Truist Financial",
            "description": "Truist Financial reaffirmed their buy rating on shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $650.00 price objective on the stock. LLY has been the subject of se\u2026",
            "url": "https://www.etfdailynews.com/2023/12/03/eli-lilly-and-company-nyselly-rating-reiterated-by-truist-financial/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-12-03T07:50:42Z",
            "content": "Truist Financial reaffirmed their buy rating on shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in a report released on Wednesday morning, Benzinga reports. The firm currently has a $650.00 \u2026 [+6352 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Eli Lilly plans new 2 billion euro German plant",
            "description": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights BERLIN, Nov 16 (Reuters) - U.S. pharmaceuticals company Eli Lilly (LLY\u2026",
            "url": "https://biztoc.com/x/20b812cbd9893c85",
            "urlToImage": "https://c.biztoc.com/p/20b812cbd9893c85/og.webp",
            "publishedAt": "2023-11-16T21:22:10Z",
            "content": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsBERLIN, Nov\u2026 [+299 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Boston Herald"
            },
            "author": "Associated Press",
            "title": "Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous",
            "description": "By TOM MURPHY (AP Health Writer) Pfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taking it. The pharmaceutical company said it will focus instead \u2026",
            "url": "https://www.bostonherald.com/2023/12/01/pfizer-nixes-more-study-of-twice-daily-obesity-pill-treatment-that-made-many-patients-nauseous/",
            "urlToImage": "https://www.bostonherald.com/wp-content/uploads/2023/12/Pfizer-Obesity_Treatment_35227.jpg?w=1024&h=682",
            "publishedAt": "2023-12-01T16:13:38Z",
            "content": "By TOM MURPHY (AP Health Writer)\r\nPfizer shares sank Friday when the drugmaker said it would abandon a twice-daily obesity treatment after more than half the patients in a clinical trial stopped taki\u2026 [+1906 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Holdings Raised by L.M. Kohn & Company",
            "description": "L.M. Kohn & Company boosted its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 27.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,826 shar\u2026",
            "url": "https://www.etfdailynews.com/2023/11/09/eli-lilly-and-company-nyselly-holdings-raised-by-l-m-kohn-company/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-09T18:50:41Z",
            "content": "L.M. Kohn &amp; Company boosted its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 27.8% in the second quarter, according to the company in its most recent Form 13F filing with the Sec\u2026 [+6966 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Retail investors crowd into Eli Lilly after weight-loss drug approval",
            "description": "The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, 2018. REUTERS/Vincent Kessler Acquire Licensing Rights Nov 1\u2026",
            "url": "https://biztoc.com/x/e2e376f9a25df11a",
            "urlToImage": "https://c.biztoc.com/p/e2e376f9a25df11a/s.webp",
            "publishedAt": "2023-11-17T13:14:06Z",
            "content": "The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. Picture taken February 1, \u2026 [+307 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Ewa LLC Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)",
            "description": "Ewa LLC boosted its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 739 shares of the company\u2019s stock after purchasing an additional 38 shares during the quarter. Ewa LLC\u2019s\u2026",
            "url": "https://www.etfdailynews.com/2023/11/20/ewa-llc-increases-stock-holdings-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-20T19:10:50Z",
            "content": "Ewa LLC boosted its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.4% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 739 shares of the company\u2019s stock after purc\u2026 [+6427 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Stone House Investment Management LLC Trims Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Stone House Investment Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 42.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 79 shares of the company\u2019s stock after selling 59 share\u2026",
            "url": "https://www.etfdailynews.com/2023/11/20/stone-house-investment-management-llc-trims-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-20T20:18:42Z",
            "content": "Stone House Investment Management LLC trimmed its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 42.8% in the second quarter, Holdings Channel.com reports. The institutional investor o\u2026 [+6589 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Railway Pension Investments Ltd Sells 2,400 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Railway Pension Investments Ltd cut its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 375,532 shares of the company\u2019s stock after selling 2,400 share\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/railway-pension-investments-ltd-sells-2400-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T19:48:43Z",
            "content": "Railway Pension Investments Ltd cut its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 375\u2026 [+6409 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) is NWK Group Inc.\u2019s 4th Largest Position",
            "description": "NWK Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 18,234 shares of the company\u2019s stock af\u2026",
            "url": "https://www.etfdailynews.com/2023/11/20/eli-lilly-and-company-nyselly-is-nwk-group-inc-s-4th-largest-position/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-20T16:58:42Z",
            "content": "NWK Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.4% during the second quarter, according to the company in its most recent Form 13F filing with the\u2026 [+6384 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Franklin Resources Inc. Has $1.50 Billion Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Franklin Resources Inc. cut its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 8.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,188,232 shares of\u2026",
            "url": "https://www.etfdailynews.com/2023/11/23/franklin-resources-inc-has-1-50-billion-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-23T17:42:58Z",
            "content": "Franklin Resources Inc. cut its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 8.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission\u2026 [+6641 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Position Decreased by Allegheny Financial Group LTD",
            "description": "Allegheny Financial Group LTD reduced its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,9\u2026",
            "url": "https://www.etfdailynews.com/2023/11/06/eli-lilly-and-company-nyselly-position-decreased-by-allegheny-financial-group-ltd/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-06T15:24:51Z",
            "content": "Allegheny Financial Group LTD reduced its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exc\u2026 [+6724 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Texas Permanent School Fund Corp Purchases 837 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Texas Permanent School Fund Corp raised its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 165,256 shares of the company\u2019s stoc\u2026",
            "url": "https://www.etfdailynews.com/2023/11/05/texas-permanent-school-fund-corp-purchases-837-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-05T17:12:42Z",
            "content": "Texas Permanent School Fund Corp raised its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.5% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The insti\u2026 [+6750 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Sold by Equitable Trust Co.",
            "description": "Equitable Trust Co. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.4% during the 2nd quarter, Holdings Channel reports. The fund owned 8,725 shares of the company\u2019s stock after selling 215 shares during the quarter. Equitab\u2026",
            "url": "https://www.etfdailynews.com/2023/11/13/eli-lilly-and-company-nyselly-shares-sold-by-equitable-trust-co/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-13T19:36:46Z",
            "content": "Equitable Trust Co. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.4% during the 2nd quarter, Holdings Channel reports. The fund owned 8,725 shares of the company\u2019\u2026 [+6476 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Winslow Asset Management Inc. Sells 594 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Winslow Asset Management Inc. cut its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 40,541 shares of the company\u2019s stock after selling 594 shares during the period. Eli L\u2026",
            "url": "https://www.etfdailynews.com/2023/11/12/winslow-asset-management-inc-sells-594-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-12T17:40:42Z",
            "content": "Winslow Asset Management Inc. cut its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.4% during the second quarter, Holdings Channel reports. The firm owned 40,541 shares of the compa\u2026 [+6082 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Sivik Global Healthcare LLC Sells 2,500 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Sivik Global Healthcare LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 12.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 17,500 shares of \u2026",
            "url": "https://www.etfdailynews.com/2023/11/12/sivik-global-healthcare-llc-sells-2500-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-12T17:40:42Z",
            "content": "Sivik Global Healthcare LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 12.5% during the second quarter, according to its most recent disclosure with the Securiti\u2026 [+6379 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Royal Capital Wealth Management LLC Has $1.50 Million Stock Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Royal Capital Wealth Management LLC grew its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 18.8% during the second quarter, Holdings Channel.com reports. The firm owned 3,194 shares of the company\u2019s stock after acquiring an additional 505 shar\u2026",
            "url": "https://www.etfdailynews.com/2023/11/28/royal-capital-wealth-management-llc-has-1-50-million-stock-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-28T18:00:42Z",
            "content": "Royal Capital Wealth Management LLC grew its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 18.8% during the second quarter, Holdings Channel.com reports. The firm owned 3,194 shares o\u2026 [+7295 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Bought by Cornerstone Advisors LLC",
            "description": "Cornerstone Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 48,700 shares of the company\u2019s stock after buyi\u2026",
            "url": "https://www.etfdailynews.com/2023/11/27/eli-lilly-and-company-nyselly-shares-bought-by-cornerstone-advisors-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-27T18:10:49Z",
            "content": "Cornerstone Advisors LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.3% during the second quarter, according to its most recent Form 13F filing with the SEC. Th\u2026 [+6802 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Glenview Trust Co Reduces Stock Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Glenview Trust Co decreased its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 211,204 s\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/glenview-trust-co-reduces-stock-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T21:28:44Z",
            "content": "Glenview Trust Co decreased its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 9.4% during the second quarter, according to its most recent filing with the Securities and Exc\u2026 [+6675 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Burney Co. Reduces Stock Holdings in Eli Lilly and Company (NYSE:LLY)",
            "description": "Burney Co. lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.1% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 38,407 shares of the company\u2019s sto\u2026",
            "url": "https://www.etfdailynews.com/2023/11/14/burney-co-reduces-stock-holdings-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-14T18:56:41Z",
            "content": "Burney Co. lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.1% during the second quarter, according to its most recent disclosure with the Securities &amp; Exchan\u2026 [+6505 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Vestor Capital LLC Sells 16,373 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Vestor Capital LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 72.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,249 shares of the company\u2019s stock after selling 16,373 shares\u2026",
            "url": "https://www.etfdailynews.com/2023/11/14/vestor-capital-llc-sells-16373-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-14T17:08:47Z",
            "content": "Vestor Capital LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 72.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,2\u2026 [+5812 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Veritable L.P. Purchases 400 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Veritable L.P. raised its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 26,651 shares of the company\u2019s stock after acquiring an add\u2026",
            "url": "https://www.etfdailynews.com/2023/11/14/veritable-l-p-purchases-400-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-14T15:26:51Z",
            "content": "Veritable L.P. raised its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned\u2026 [+6436 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Nvwm LLC Sells 513 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Nvwm LLC reduced its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,947 shares of the c\u2026",
            "url": "https://www.etfdailynews.com/2023/11/09/nvwm-llc-sells-513-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-09T17:01:11Z",
            "content": "Nvwm LLC reduced its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commis\u2026 [+7290 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Stock Holdings Lowered by Epoch Investment Partners Inc.",
            "description": "Epoch Investment Partners Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 4.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 382,720 shares of the company\u2019s stock after sellin\u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/eli-lilly-and-company-nyselly-stock-holdings-lowered-by-epoch-investment-partners-inc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T15:59:05Z",
            "content": "Epoch Investment Partners Inc. lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 4.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The f\u2026 [+6912 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Genus Capital Management Inc. Takes $12.31 Million Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Genus Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 26,238 shares of the co\u2026",
            "url": "https://www.etfdailynews.com/2023/11/30/genus-capital-management-inc-takes-12-31-million-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-30T17:56:48Z",
            "content": "Genus Capital Management Inc. acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC.\u2026 [+6877 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Korea Investment CORP Has $381.85 Million Stock Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Korea Investment CORP reduced its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.0% during the 2nd quarter, Holdings Channel reports. The firm owned 814,213 shares of the company\u2019s stock after selling 60,969 shares during the period. Eli Lilly a\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/korea-investment-corp-has-381-85-million-stock-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T22:14:42Z",
            "content": "Korea Investment CORP reduced its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 7.0% during the 2nd quarter, Holdings Channel reports. The firm owned 814,213 shares of the company\u2019s stoc\u2026 [+6004 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "BRYN MAWR TRUST Co Sells 716 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "BRYN MAWR TRUST Co lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 3.6% during the second quarter, HoldingsChannel.com reports. The fund owned 19,226 shares of the company\u2019s stock after selling 716 shares during the quarter\u2026",
            "url": "https://www.etfdailynews.com/2023/11/27/bryn-mawr-trust-co-sells-716-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-27T19:14:52Z",
            "content": "BRYN MAWR TRUST Co lowered its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 3.6% during the second quarter, HoldingsChannel.com reports. The fund owned 19,226 shares of the\u2026 [+6631 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "MYDA Advisors LLC Acquires New Shares in Eli Lilly and Company (NYSE:LLY)",
            "description": "MYDA Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 14,000 shares of the company\u2019s stock, valued at approxim\u2026",
            "url": "https://www.etfdailynews.com/2023/11/27/myda-advisors-llc-acquires-new-shares-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-27T16:52:41Z",
            "content": "MYDA Advisors LLC acquired a new stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor acqui\u2026 [+6550 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Purchased by Bleakley Financial Group LLC",
            "description": "Bleakley Financial Group LLC lifted its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 53,070 shares of the company\u2019s stock after purchasing an additional 1,165 shares during th\u2026",
            "url": "https://www.etfdailynews.com/2023/12/04/eli-lilly-and-company-nyselly-shares-purchased-by-bleakley-financial-group-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-12-04T19:04:42Z",
            "content": "Bleakley Financial Group LLC lifted its stake in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.2% in the 2nd quarter, Holdings Channel.com reports. The firm owned 53,070 shares of the company\u2019s\u2026 [+7069 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Lilly to Participate in Evercore ISI HealthCONx Conference",
            "description": "(marketscreener.com) \n\nINDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company will attend\u00a0the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023.\u00a0Daniel Skovronsky, M.D., Ph.D., executive vice president, chief scientific and medical o\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-to-Participate-in-Evercore-ISI-HealthCONx-Conference-45349868/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-14T15:01:09Z",
            "content": "INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend\u00a0the sixth annual Evercore ISI HealthCONx Conference on Nov. 28, 2023.\u00a0Daniel Skovronsky, M.D., Ph.D., executi\u2026 [+1967 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Eli Lilly: to open a new laboratory in San Diego",
            "description": "(marketscreener.com) Eli Lilly today announced plans to open a new 'Gateway Labs' laboratory in San Diego, California, in the first half of 2024. Gateway Labs will be a shared innovation gas pedal: it will provide participating companies with state-of-the-art\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-to-open-a-new-laboratory-in-San-Diego-45451969/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-28T13:56:03Z",
            "content": "Eli Lilly today announced plans to open a new 'Gateway Labs' laboratory in San Diego, California, in the first half of 2024. Gateway Labs will be a shared innovation gas pedal: it will provide partic\u2026 [+462 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "This Biotech Stock Nears A Buy Point After 200% Profit Growth",
            "description": "This biotech stock is in a base after the company produced triple-digit earnings growth.",
            "url": "https://www.investors.com/stock-lists/sector-leaders/this-biotech-stock-nears-a-buy-point-after-profit-growth/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2023/06/Stock-amphastarpharma-01-shutt.jpg",
            "publishedAt": "2023-11-30T23:13:50Z",
            "content": "Biotech Amphastar Pharmaceuticals (AMPH) sits in a base after a big earnings move and is poised for a breakout. The IBD Sector Leader gained around 24% since its earnings report in early November.\r\nX\u2026 [+2573 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Avalon Global Asset Management LLC Makes New $4.69 Million Investment in Eli Lilly and Company (NYSE:LLY)",
            "description": "Avalon Global Asset Management LLC bought a new position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 10,000 sh\u2026",
            "url": "https://www.etfdailynews.com/2023/11/28/avalon-global-asset-management-llc-makes-new-4-69-million-investment-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-28T20:56:49Z",
            "content": "Avalon Global Asset Management LLC bought a new position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exch\u2026 [+7053 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Sold by Credit Suisse AG",
            "description": "Credit Suisse AG reduced its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,631,327 shares of\u2026",
            "url": "https://www.etfdailynews.com/2023/11/28/eli-lilly-and-company-nyselly-shares-sold-by-credit-suisse-ag/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-28T19:10:57Z",
            "content": "Credit Suisse AG reduced its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission\u2026 [+6840 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Baird Financial Group Inc. Sells 28,058 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Baird Financial Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 12.3% during the second quarter, HoldingsChannel reports. The fund owned 200,876 shares of the company\u2019s stock after selling 28,058 shares during th\u2026",
            "url": "https://www.etfdailynews.com/2023/11/29/baird-financial-group-inc-sells-28058-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-29T21:53:13Z",
            "content": "Baird Financial Group Inc. trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 12.3% during the second quarter, HoldingsChannel reports. The fund owned 200,876 shares \u2026 [+7010 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Decatur Capital Management Inc. Acquires New Stake in Eli Lilly and Company (NYSE:LLY)",
            "description": "Decatur Capital Management Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 5,530 shares of the com\u2026",
            "url": "https://www.etfdailynews.com/2023/11/14/decatur-capital-management-inc-acquires-new-stake-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-14T20:08:41Z",
            "content": "Decatur Capital Management Inc. bought a new position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) in the second quarter, according to the company in its most recent filing with the SE\u2026 [+6158 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Lokken Investment Group LLC Has $2.23 Million Stake in Eli Lilly and Company (NYSE:LLY)",
            "description": "Lokken Investment Group LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 3.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,764 shares of the company\u2019s st\u2026",
            "url": "https://www.etfdailynews.com/2023/11/12/lokken-investment-group-llc-has-2-23-million-stake-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-12T15:28:50Z",
            "content": "Lokken Investment Group LLC reduced its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 3.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange\u2026 [+6379 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Fortress Wealth Group LLC Has $1.08 Million Holdings in Eli Lilly and Company (NYSE:LLY)",
            "description": "Fortress Wealth Group LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,381 shares of the company\u2019s stock after selling 23 sh\u2026",
            "url": "https://www.etfdailynews.com/2023/11/15/fortress-wealth-group-llc-has-1-08-million-holdings-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-15T16:42:42Z",
            "content": "Fortress Wealth Group LLC lessened its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.0% in the second quarter, according to its most recent filing with the SEC. The firm o\u2026 [+6613 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Stevard LLC Has $461,000 Stock Position in Eli Lilly and Company (NYSE:LLY)",
            "description": "Stevard LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 982 shares of the company\u2019s stock after buying an\u2026",
            "url": "https://www.etfdailynews.com/2023/11/23/stevard-llc-has-461000-stock-position-in-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-23T21:14:43Z",
            "content": "Stevard LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 2.3% in the second quarter, according to its most recent disclosure with the SEC. The institutional inve\u2026 [+6362 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Capital International Inc. CA Acquires 19,712 Shares of Eli Lilly and Company (NYSE:LLY)",
            "description": "Capital International Inc. CA raised its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 22.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 106,4\u2026",
            "url": "https://www.etfdailynews.com/2023/11/22/capital-international-inc-ca-acquires-19712-shares-of-eli-lilly-and-company-nyselly/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-22T19:35:09Z",
            "content": "Capital International Inc. CA raised its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 22.7% during the second quarter, according to its most recent disclosure with the Securities and\u2026 [+6633 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Holdings Increased by Element Capital Management LLC",
            "description": "Element Capital Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 105,657 shares of the company\u2019s stock after\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/eli-lilly-and-company-nyselly-holdings-increased-by-element-capital-management-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T20:56:44Z",
            "content": "Element Capital Management LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 5.4% in the second quarter, according to its most recent filing with the SEC. The institutiona\u2026 [+6320 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Sold by Northern Trust Corp",
            "description": "Northern Trust Corp trimmed its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 6.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,802,958 shares of the company\u2019s sto\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/eli-lilly-and-company-nyselly-shares-sold-by-northern-trust-corp/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T19:48:43Z",
            "content": "Northern Trust Corp trimmed its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 6.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Comm\u2026 [+6010 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Point Biopharma Holders Resisting Eli Lilly Tender Offer",
            "description": "(marketscreener.com) \n By Colin Kellaher \n\n\n Eli Lilly's planned $1.4 billion acquisition of Point Biopharma Global has hit a speed bump, as the radiopharmaceutical company's shareholders appear to not be going along with the tender offer. \n\n Eli Lilly on Fri\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Point-Biopharma-Holders-Resisting-Eli-Lilly-Tender-Offer-45385370/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-17T13:34:02Z",
            "content": "By Colin Kellaher \r\nEli Lilly's planned $1.4 billion acquisition of Point Biopharma Global has hit a speed bump, as the radiopharmaceutical company's shareholders appear to not be going along with th\u2026 [+1467 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Investor's Business Daily"
            },
            "author": "Investor's Business Daily",
            "title": "Top Funds Can't Get Enough Of Amazon \u2014 And This Intelligence Play",
            "description": "As a Santa Claus rally begins, the AI boom continues to fuel gains for Palantir and Amazon.",
            "url": "https://www.investors.com/etfs-and-funds/mutual-funds/amazon-stock-palantir-oracle-and-this-auctioneer-lead-list-of-new-buys-by-the-best-mutual-funds/",
            "urlToImage": "https://www.investors.com/wp-content/uploads/2023/11/Stock-santapresents-01-adobe.jpg",
            "publishedAt": "2023-11-10T15:12:24Z",
            "content": "Just in time for a Santa Claus rally and the holiday shopping season, the best mutual funds have placed a massive bet on online retailer and cloud giant Amazon.com (AMZN). The latest list of new buys\u2026 [+3170 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Stock Position Raised by Column Capital Advisors LLC",
            "description": "Column Capital Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 787,836 shares of the company\u2019s\u2026",
            "url": "https://www.etfdailynews.com/2023/11/08/eli-lilly-and-company-nyselly-stock-position-raised-by-column-capital-advisors-llc/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-08T23:18:42Z",
            "content": "Column Capital Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 0.1% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The \u2026 [+7388 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Lilly extends tender offer to acquire Point Biopharma to Dec 1",
            "description": "(marketscreener.com) Eli Lilly said on Friday it\nwas extending the deadline for its tender offer for Point\nBiopharma shares to Dec. 1, from Nov. 16 previously.\n In October, Lilly agreed to acquire the company in an\nall-cash deal valued at $1.4 billion.\n \n htt\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-extends-tender-offer-to-acquire-Point-Biopharma-to-Dec-1-45384358/",
            "urlToImage": "https://www.marketscreener.com/images/reuters/2021-03/2021-03-09T172726Z_1_LYNXMPEH2814Y-OCABS_RTROPTP_3_CBUSINESS-US-LILLY-MOVES.JPG",
            "publishedAt": "2023-11-17T11:59:20Z",
            "content": "Nov 17 (Reuters) - Eli Lilly said on Friday it\r\nwas extending the deadline for its tender offer for Point\r\nBiopharma shares to Dec. 1, from Nov. 16 previously.\r\nIn October, Lilly agreed to acquire th\u2026 [+95 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany",
            "description": "(marketscreener.com) \n\nCompany also commits to investing up to $100 million in German early-stage life sciences ecosystem \nINDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company today announced plans to construct a new $2.5 billion high-tech manufa\u2026",
            "url": "https://www.marketscreener.com/quote/stock/ELI-LILLY-AND-COMPANY-13401/news/Lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-Germany-45384954/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-17T13:01:07Z",
            "content": "Company also commits to investing up to $100 million in German early-stage life sciences ecosystem \r\nINDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced plan\u2026 [+7431 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Eli Lilly and Company (NYSE:LLY) Shares Acquired by Bradley Foster & Sargent Inc. CT",
            "description": "Bradley Foster & Sargent Inc. CT boosted its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 21,318 shares of the company\u2019s stock after acquiring an additional 373 shares\u2026",
            "url": "https://www.etfdailynews.com/2023/11/09/eli-lilly-and-company-nyselly-shares-acquired-by-bradley-foster-sargent-inc-ct/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/logo_eli_lilly.jpg&w=240&h=240&zc=2",
            "publishedAt": "2023-11-09T14:02:48Z",
            "content": "Bradley Foster &amp; Sargent Inc. CT boosted its position in shares of Eli Lilly and Company (NYSE:LLY \u2013 Free Report) by 1.8% in the 2nd quarter, HoldingsChannel reports. The fund owned 21,318 shares\u2026 [+6782 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Biztoc.com"
            },
            "author": "reuters.com",
            "title": "Lilly extends tender offer to acquire Point Biopharma to Dec 1",
            "description": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing Rights Nov 17 (Reuters) - Eli Lilly (LLY.N) said on Friday it was extending t\u2026",
            "url": "https://biztoc.com/x/69a0d9583523307d",
            "urlToImage": "https://c.biztoc.com/p/69a0d9583523307d/s.webp",
            "publishedAt": "2023-11-17T12:18:07Z",
            "content": "An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsNov 17 (Reu\u2026 [+306 chars]"
        }
    ]
}